Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLNASDAQ:EGRXNASDAQ:EXOZNASDAQ:IVVD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.45-1.0%$1.14$0.77▼$2.63$119.43M1.03326,872 shs24,888 shsEGRXEagle Pharmaceuticals$2.35-2.1%$1.87$1.50▼$2.50$30.52M0.839,590 shs6,047 shsEXOZExozymes$12.77-0.3%$12.68$8.50▼$23.99$106.86MN/A17,015 shs993 shsIVVDInvivyd$0.79+0.3%$0.71$0.35▼$2.74$95.49M0.634.54 million shs581,640 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%+3.55%+31.53%+24.79%-39.42%EGRXEagle Pharmaceuticals0.00%+6.67%+23.71%+60.00%-37.66%EXOZExozymes0.00%-4.69%-14.83%-9.79%+1,280,999,900.00%IVVDInvivyd0.00%-19.95%+1.97%+3.64%-49.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.2566 of 5 stars3.72.00.00.03.30.00.6EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AIVVDInvivyd3.7531 of 5 stars3.64.00.00.02.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.40Buy$8.67499.77% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/AEXOZExozymes 0.00N/AN/AN/AIVVDInvivyd 3.25Buy$5.85636.78% UpsideCurrent Analyst Ratings BreakdownLatest EGRX, EXOZ, CRDL, and IVVD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/28/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $5.005/16/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/20/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AEGRXEagle Pharmaceuticals$257.55M0.12$5.88 per share0.40N/A∞EXOZExozymesN/AN/AN/AN/AN/AN/AIVVDInvivyd$36.69M2.60N/AN/A$1.61 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AEXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AIVVDInvivyd-$198.64M-$1.20N/A7.22N/AN/A-155.33%-114.88%8/13/2025 (Estimated)Latest EGRX, EXOZ, CRDL, and IVVD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IVVDInvivyd-$0.04-$0.14-$0.10-$0.14$34.45 million$11.30 million5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A3/20/2025Q4 2024IVVDInvivyd-$0.25-$0.15+$0.10-$0.15$13.57 million$13.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.012.492.49EGRXEagle PharmaceuticalsN/AN/AN/AEXOZExozymesN/AN/AN/AIVVDInvivydN/A1.921.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%EGRXEagle Pharmaceuticals85.36%EXOZExozymesN/AIVVDInvivyd70.36%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%EGRXEagle Pharmaceuticals28.90%EXOZExozymesN/AIVVDInvivyd25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.65 million78.27 millionNot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataEXOZExozymes298.37 millionN/AN/AIVVDInvivyd100119.96 million98.21 millionOptionableEGRX, EXOZ, CRDL, and IVVD HeadlinesRecent News About These CompaniesInvivyd, Inc. (NASDAQ:IVVD) Shares Acquired by Two Sigma Advisers LPJune 8, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for InvivydMay 31, 2025 | marketbeat.comQ1 Earnings Estimate for Invivyd Issued By HC WainwrightMay 30, 2025 | marketbeat.comH.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue ShortfallMay 29, 2025 | msn.comInvivyd (NASDAQ:IVVD) Price Target Cut to $5.00 by Analysts at HC WainwrightMay 29, 2025 | marketbeat.comInvivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 VirusMay 27, 2025 | globenewswire.comInvivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network®May 23, 2025 | bakersfield.comInvivyd, Inc. Announces Inclusion of PEMGARDA® in NCCN Clinical Practice Guidelines for B-Cell LymphomasMay 23, 2025 | quiverquant.comInvivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell LymphomasMay 23, 2025 | globenewswire.comInvivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster EfficacyMay 23, 2025 | nasdaq.comInvivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19May 21, 2025 | globenewswire.comEarnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings missMay 16, 2025 | investing.comInvivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comInvivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...May 16, 2025 | finance.yahoo.comInvivyd Reports Q1 2025 Financial Results and OutlookMay 16, 2025 | tipranks.comINVIVYD Earnings Preview: Recent $IVVD Insider Trading, Hedge Fund Activity, and MoreMay 15, 2025 | nasdaq.comInvivyd, Inc. (IVVD) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comInvivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comInvivyd Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comInvivyd, Inc. Submits Citizen Petition to FDA Advocating for Updated COVID-19 Vaccine Development StrategiesMay 14, 2025 | quiverquant.comInvivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine EfficacyMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGRX, EXOZ, CRDL, and IVVD Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.44 -0.02 (-1.03%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Eagle Pharmaceuticals NASDAQ:EGRX$2.35 -0.05 (-2.08%) As of 09:51 AM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Exozymes NASDAQ:EXOZ$12.77 -0.04 (-0.31%) As of 11:25 AM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Invivyd NASDAQ:IVVD$0.79 +0.00 (+0.25%) As of 12:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
